T1	Condition 21 40	Alzheimer's disease
T2	Measurement 42 195	National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
R1	AND Arg1:T1 Arg2:T2	
T3	Value 12 20	probable
T4	Value 0 8	Possible
*	OR T3 T4
T5	Scope 0 20	Possible or probable
R2	Has_scope Arg1:T2 Arg2:T5	
T6	Measurement 203 232	Mini-Mental State Exam (MMSE)
T7	Value 233 257	score of 10-26 inclusive
T8	Measurement 259 263	MMSE
T9	Value 264 279	scores above 26
R3	Has_value Arg1:T8 Arg2:T9	
R4	Has_value Arg1:T6 Arg2:T7	
*	OR T6 T8
T10	Condition 324 326	AD
T11	Condition 423 429	apathy
T12	Person 434 453	at least four weeks
T13	Measurement 517 549	Neuropsychiatric Inventory (NPI)
T14	Value 554 569	Very frequently
R5	Has_value Arg1:T13 Arg2:T14	
T15	Measurement 621 624	NPI
T16	Value 629 639	Frequently
T17	Value 645 650	Often
*	OR T17 T16
T18	Measurement 698 701	NPI
T19	Observation 660 678	severity of apathy
T20	Observation 582 601	frequency of apathy
R6	AND Arg1:T20 Arg2:T15	
T21	Scope 628 651	'Frequently' or 'Often'
T22	Value 706 714	Moderate
T23	Value 720 726	Marked
*	OR T23 T22
T24	Scope 705 727	'Moderate' or 'Marked'
R7	Has_scope Arg1:T18 Arg2:T24	
R8	Has_scope Arg1:T15 Arg2:T21	
R9	AND Arg1:T19 Arg2:T18	
T25	Scope 582 727	frequency of apathy as assessed by the NPI is 'Frequently' or 'Often' AND the severity of apathy as assessed by the NPI is 'Moderate' or 'Marked'
T26	Observation 478 497	frequency of apathy
R10	AND Arg1:T26 Arg2:T13	
*	OR T26 T25
T27	Drug 731 752	medication for apathy
T28	Condition 746 752	apathy
R11	AND Arg1:T27 Arg2:T28	
T29	Post-eligibility 729 806	A medication for apathy is appropriate, in the opinion of the study physician
T30	Parsing_Error 729 806	A medication for apathy is appropriate, in the opinion of the study physician
T31	Post-eligibility 808 961	Provision of informed consent for participation in the study by patient or surrogate (if the patient is unable to provide informed consent) and caregiver
T32	Post-eligibility 963 1157	Availability of primary caregiver, who spends greater than ten hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study
T33	Post-eligibility 1159 1315	Sufficient fluency, of both the patient and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments
T34	Drug 1330 1344	AD medications
T35	Temporal 1345 1385	within the month preceding randomization
T36	Reference_point 1372 1385	randomization
R12	Has_index Arg1:T35 Arg2:T36	
T37	Observation 1320 1344	change to AD medications
T38	Negation 1317 1319	No
R13	Has_negation Arg1:T37 Arg2:T38	
R14	AND Arg1:T37 Arg2:T34	
R15	Has_temporal Arg1:T37 Arg2:T35	
T39	Drug 1473 1534	selective serotonin reuptake inhibitor antidepressants(SSRIs)
T40	Qualifier 1457 1469	stable doses
T41	Procedure 1442 1451	Treatment
R16	AND Arg1:T41 Arg2:T39	
R17	Has_qualifier Arg1:T39 Arg2:T40	
T42	Context_Error 1442 1757	Treatment with stable doses of selective serotonin reuptake inhibitor antidepressants(SSRIs) is appropriate if stable for 3 months prior to randomization. Other psychotropics(with the exclusion of antipsychotics), if stable for 3 months, may be allowed only with Steering Committee approval on a case by case basis.
